[{"id":"8b6df141-7b64-4f9b-89f3-9e3e39a78d70","acronym":"NCI-2017-00831","url":"https://clinicaltrials.gov/study/NCT03066206","created_at":"2021-01-17T17:10:50.278Z","updated_at":"2024-07-02T16:35:01.092Z","phase":"Phase 2","brief_title":"Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC","source_id_and_acronym":"NCT03066206 - NCI-2017-00831","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"0e951a08-185b-43b0-abfd-bacd8cecb2d9","acronym":"PINNACLE","url":"https://clinicaltrials.gov/study/NCT05378763","created_at":"2022-05-18T13:00:48.132Z","updated_at":"2024-07-02T16:35:19.182Z","phase":"Phase 3","brief_title":"A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations","source_id_and_acronym":"NCT05378763 - PINNACLE","lead_sponsor":"Spectrum Pharmaceuticals, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Pozenveo (poziotinib)"],"overall_status":"Suspended","enrollment":" Enrollment 268","initiation":"Initiation: 05/12/2022","start_date":" 05/12/2022","primary_txt":" Primary completion: 12/25/2027","primary_completion_date":" 12/25/2027","study_txt":" Completion: 12/25/2028","study_completion_date":" 12/25/2028","last_update_posted":"2024-02-15"},{"id":"68a651a8-1387-4fda-96e1-3577707db322","acronym":"","url":"https://clinicaltrials.gov/study/NCT05045404","created_at":"2021-09-16T15:55:27.556Z","updated_at":"2024-07-02T16:35:37.117Z","phase":"Phase 2","brief_title":"Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05045404","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Pozenveo (poziotinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 02/02/2023","study_completion_date":" 02/02/2023","last_update_posted":"2023-09-13"},{"id":"2ea36251-0a37-4f01-ac02-6a770fb828cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03292250","created_at":"2021-01-18T16:15:56.076Z","updated_at":"2024-07-02T16:36:14.544Z","phase":"Phase 2","brief_title":"Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]","source_id_and_acronym":"NCT03292250","lead_sponsor":"Seoul National University Hospital","biomarkers":" HER-2 • FGFR","pipe":" | ","alterations":" CDKN2A negative","tags":["HER-2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • Imjudo (tremelimumab-actl) • nintedanib • Pozenveo (poziotinib)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 09/10/2017","start_date":" 09/10/2017","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/10/2022","study_completion_date":" 03/10/2022","last_update_posted":"2022-03-29"},{"id":"1900325e-e2d0-44ec-828f-b3c2325be47b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02544997","created_at":"2021-01-18T12:18:45.719Z","updated_at":"2024-07-02T16:36:43.567Z","phase":"Phase 2","brief_title":"A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway","source_id_and_acronym":"NCT02544997","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 amplification • EGFR expression • EGFR overexpression • AR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 amplification • EGFR expression • EGFR overexpression • AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2020-07-07"},{"id":"cc5002b8-cbec-46be-9880-77ff02da992c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02216916","created_at":"2022-06-01T07:55:39.164Z","updated_at":"2024-07-02T16:37:01.641Z","phase":"Phase 2","brief_title":"Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy","source_id_and_acronym":"NCT02216916","lead_sponsor":"Yonsei University","biomarkers":" EGFR • HER-2 • CDH1","pipe":" | ","alterations":" KRAS mutation","tags":["EGFR • HER-2 • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 49","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2019-03-18"},{"id":"00626ca3-069f-4825-b43a-05ec1a54dfc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02979821","created_at":"2021-01-18T14:39:30.107Z","updated_at":"2024-07-02T16:37:10.509Z","phase":"Phase 2","brief_title":"Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)","source_id_and_acronym":"NCT02979821","lead_sponsor":"Korean Association for the Study of Targeted Therapy","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-05-24"}]